Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEB7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $158,740
Award facts
- Contract value 100% obligated
- $158,740.09 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $158,740.09 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The contract, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, utilizes a firm fixed-price structure with no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award contract valued at $499.999 billion through December 31, 2036, which positions the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, demonstrates substantial federal contracting capability through its established performance supplying a comprehensive portfolio of pharmaceuticals and medical consumables to military healthcare facilities. The company's product offerings encompass branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with Keytruda representing one of its oncology treatment offerings. As a qualified prime vendor under the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group leverages its small business status to support recurring medical supply needs of the Department of Defense across multiple therapeutic categories and geographic regions.
Quick answers
Who was awarded contract SPE2DR26FMEB7?
SPE2DR26FMEB7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FMEB7 worth?
The government has obligated $158,740 on SPE2DR26FMEB7.
Is contract SPE2DR26FMEB7 an order under another contract?
Yes. SPE2DR26FMEB7 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEB7 competed?
The extent of competition for SPE2DR26FMEB7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award